A Pilot Trial of HU14.18-IL2 (EMD273063) in Subjects With Completely Resectable Recurrent Stage III or Stage IV Melanoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 27 Sep 2018
At a glance
- Drugs Monoclonal antibody ch14 18 interleukin-2 fusion protein (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 03 Jun 2015 Planned End Date changed from 1 Dec 2011 to 1 Jan 2020 as per ClinicalTrials.gov record.
- 03 Jun 2015 Status changed from completed to active, no longer recruiting as per ClinicalTrials.gov record.
- 03 Jun 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.